Literature DB >> 23237991

Experimental therapies for yellow fever.

Justin G Julander1.   

Abstract

A number of viruses in the family Flaviviridae are the focus of efforts to develop effective antiviral therapies. Success has been achieved with inhibitors for the treatment of hepatitis C, and there is interest in clinical trials of drugs against dengue fever. Antiviral therapies have also been evaluated in patients with Japanese encephalitis and West Nile encephalitis. However, no treatment has been developed against the prototype flavivirus, yellow fever virus (YFV). Despite the availability of the live, attenuated 17D vaccine, thousands of cases of YF continue to occur each year in Africa and South America, with a significant mortality rate. In addition, a small number of vaccinees develop severe systemic infections with the 17D virus. This paper reviews current efforts to develop antiviral therapies, either directly targeting the virus or blocking detrimental host responses to infection.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23237991      PMCID: PMC3563926          DOI: 10.1016/j.antiviral.2012.12.002

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  111 in total

Review 1.  Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

Authors:  Alan D T Barrett; Dirk E Teuwen
Journal:  Curr Opin Immunol       Date:  2009-06-10       Impact factor: 7.486

2.  Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients.

Authors:  Jérôme Pacanowski; Karine Lacombe; Pauline Campa; Magdalena Dabrowska; Jean-Dominique Poveda; Jean-Luc Meynard; Jean-Louis Poirot; Laurent Fonquernie; Pierre-Marie Girard
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

3.  Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

Authors:  Claire Pierra; Agnès Amador; Samira Benzaria; Erika Cretton-Scott; Marc D'Amours; John Mao; Steven Mathieu; Adel Moussa; Edward G Bridges; David N Standring; Jean-Pierre Sommadossi; Richard Storer; Gilles Gosselin
Journal:  J Med Chem       Date:  2006-11-02       Impact factor: 7.446

Review 4.  An overview of emerging therapies for the treatment of chronic hepatitis C.

Authors:  Jawad A Ilyas; John M Vierling
Journal:  Clin Liver Dis       Date:  2011-08       Impact factor: 6.126

5.  Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.

Authors:  Victor E Buckwold; Jiayi Wei; Zhuhui Huang; Chunsheng Huang; Aysegul Nalca; Jay Wells; Julie Russell; Barbara Collins; Roger Ptak; William Lang; Curtis Scribner; Dennis Blanchett; Tom Alessi; Peter Langecker
Journal:  Antiviral Res       Date:  2006-09-11       Impact factor: 5.970

6.  Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values.

Authors:  Elena Sbrana; Shu-Yuan Xiao; Vsevolod L Popov; Patrick C Newman; Robert B Tesh
Journal:  Am J Trop Med Hyg       Date:  2006-06       Impact factor: 2.345

7.  Error-prone replication of West Nile virus caused by ribavirin.

Authors:  Craig W Day; Donald F Smee; Justin G Julander; Vladimir F Yamshchikov; Robert W Sidwell; John D Morrey
Journal:  Antiviral Res       Date:  2005-07       Impact factor: 5.970

8.  The flaviviral methyltransferase is a substrate of Casein Kinase 1.

Authors:  Dipankar Bhattacharya; Israrul H Ansari; Rob Striker
Journal:  Virus Res       Date:  2009-01-29       Impact factor: 3.303

9.  Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.

Authors:  John D Morrey; Venkatraman Siddharthan; Aaron L Olsen; Hong Wang; Justin G Julander; Jeffery O Hall; Hua Li; Jeffrey L Nordstrom; Scott Koenig; Syd Johnson; Michael S Diamond
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

10.  PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.

Authors:  Angela M Lam; Eisuke Murakami; Christine Espiritu; Holly M Micolochick Steuer; Congrong Niu; Meg Keilman; Haiying Bao; Veronique Zennou; Nigel Bourne; Justin G Julander; John D Morrey; Donald F Smee; David N Frick; Julie A Heck; Peiyuan Wang; Dhanapalan Nagarathnam; Bruce S Ross; Michael J Sofia; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

View more
  13 in total

1.  BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.

Authors:  Justin G Julander; Shanta Bantia; Brian R Taubenheim; Dena M Minning; Pravin Kotian; John D Morrey; Donald F Smee; William P Sheridan; Yarlagadda S Babu
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

Authors:  Irina Tretyakova; Brian Nickols; Rachmat Hidajat; Jenny Jokinen; Igor S Lukashevich; Peter Pushko
Journal:  Virology       Date:  2014-08-16       Impact factor: 3.616

3.  Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.

Authors:  Justin G Julander; Brett A Thibodeaux; John D Morrey; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2014-01-03       Impact factor: 5.970

4.  A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein.

Authors:  Fang Guo; Shuo Wu; Justin Julander; Julia Ma; Xuexiang Zhang; John Kulp; Andrea Cuconati; Timothy M Block; Yanming Du; Ju-Tao Guo; Jinhong Chang
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

5.  A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Authors:  Amanda E Calvert; Kandice L Dixon; Joseph Piper; Susan L Bennett; Brett A Thibodeaux; Alan D T Barrett; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2016-04-26       Impact factor: 5.970

6.  A DNA vaccine against yellow fever virus: development and evaluation.

Authors:  Milton Maciel; Fábia da Silva Pereira Cruz; Marli Tenório Cordeiro; Márcia Archer da Motta; Klécia Marília Soares de Melo Cassemiro; Rita de Cássia Carvalho Maia; Regina Célia Bressan Queiroz de Figueiredo; Ricardo Galler; Marcos da Silva Freire; Joseph Thomas August; Ernesto T A Marques; Rafael Dhalia
Journal:  PLoS Negl Trop Dis       Date:  2015-04-13

Review 7.  Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention.

Authors:  Joanna Zmurko; Johan Neyts; Kai Dallmeier
Journal:  Rev Med Virol       Date:  2015-04-01       Impact factor: 6.989

8.  Synthesis and insecticidal activity of acridone derivatives to Aedes aegypti and Culex quinquefasciatus larvae and non-target aquatic species.

Authors:  Selvaraj Mohana Roopan; Annadurai Bharathi; Naif Abdullah Al-Dhabi; Mariadhas Valan Arasu; G Madhumitha
Journal:  Sci Rep       Date:  2017-01-06       Impact factor: 4.379

Review 9.  Current Status of Dengue Therapeutics Research and Development.

Authors:  Jenny G H Low; Eng Eong Ooi; Subhash G Vasudevan
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

Review 10.  Antivirals against Chikungunya Virus: Is the Solution in Nature?

Authors:  Daniel Oliveira Silva Martins; Igor de Andrade Santos; Débora Moraes de Oliveira; Victória Riquena Grosche; Ana Carolina Gomes Jardim
Journal:  Viruses       Date:  2020-02-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.